Q-omics provides the consensus-scored LINC01116 profile across patient tissues and cancer cell-line models. LINC01116 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01116 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LINC01116 RNA expression shows 15,108 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where LINC01116 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01116 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01116 survival associations across molecular data types. LINC01116 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01116 RNA expression–survival associations across cancer types. High LINC01116 expression shows unfavorable associations in KIRP, UCEC, UVM, LIHC, BLCA and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01116 RNA expression.
This table summarizes LINC01116 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01116. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01116 shows lower tumor expression in KICH and UCEC and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher LINC01116 RNA expression in tumor versus normal tissue (log2 FC = +3.471, t-test p < 0.001).
This table shows molecular features associated with LINC01116 in patient tissues and cancer cell lines. In patient samples, LINC01116 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01116 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
